• Improving on "Natural" Rodent Antibodies
• 26 min
  1. The immunogenicity problem in antibody therapy

  • Prof. Herman Waldmann
• 32 min
  2. Antibodies by protein engineering

  • Prof. Sir Gregory Winter
• 60 min
  3. The generation of diversity in antibody genes

  • Prof. Michael Neuberger
• 51 min
  4. Innate immunity to retroelements by human AID/APOBEC3 proteins

  • Prof. Reuben Harris
• 36 min
  5. Fc receptors and antibody effector functions

  • Dr. Mike Clark
• 57 min
  6. Antibody engineering of Fc effector functions

  • Dr. Mike Clark
• 35 min
  7. Antibody engineering: beginnings to bispecifics and beyond

  • Dr. Ian Wilkinson
• Antibodies in Cancer Therapy
• 41 min
  8. Monoclonal antibodies and the ErbB system in human cancer

  • Prof. Mark Greene
• 71 min
  9. Checkpoint blockade in cancer immunotherapy

  • Prof. James Allison
• 45 min
  10. Monoclonal antibodies in haemato-oncology

  • Prof. Mark Cragg
• Diagnostic Antibodies
• 46 min
  11. Monitoring therapy with antibodies

  • Dr. Geoffrey Hale
• Cell Surface Glycoproteins on Cells of the Immune System
• 38 min
  12. Cell surface glycoproteins on cells of the immune system

  • Prof. Neil Barclay
• Antibodies as Immunosuppressants
• 29 min
  13. Monoclonal antibodies to induce therapeutic immunological tolerance

  • Prof. Herman Waldmann
• 29 min
  14. Antibodies to control or prevent type 1 diabetes

  • Dr. Robert Hilbrands
• 48 min
  15. Antibody therapy of multiple sclerosis

  • Dr. Alasdair Coles
  • Prof. Alastair Compston
• 42 min
  16. Monoclonal antibodies in the management of rheumatoid arthritis

  • Prof. John Isaacs
• 40 min
  17. Modern management of rheumatoid arthritis - with a focus on biologic therapies

  • Prof. John Isaacs
• 30 min
  18. Tolerance induction to clotting factors with monoclonal antibodies

  • Prof. Luis Graca
• Archived Lectures *These may not cover the latest advances in the field
• 26 min
  19. Alemtuzumab (Campath-1H) in therapy of CLL

  • Prof. Kanti Rai
• 71 min
  20. VEGF inhibitors for anti-angiogenic therapy

  • Prof. Kari Alitalo
  • Dr. Bronislaw Pytowski
• 26 min
  21. Human antibodies produced in mice

  • Dr. Marianne Bruggemann
• 52 min
  22. New strategies to prevent transplant rejection: from molecules to mice to monkeys to man

  • Prof. Christian Larsen
• 55 min
  23. CD20 antibodies in the targeting of B-cell malignancies and autoimmunity

  • Prof. Thomas Tedder
• 45 min
  24. Anti-IL-2 receptor antibodies as models for cancer therapy

  • Prof. Thomas Waldmann
• 58 min
  25. Anti TNF therapy in rheumatoid arthritis

  • Prof. Marc Feldmann
• 36 min
  26. Novel immunotherapeutic proteins: immunoligand

  • Prof. Terry Strom
• 21 min
  27. Diagnostic immunohistopathology

  • Prof. David Mason
• 56 min
  28. Antibodies in the control of type I diabetes

  • Prof. Lucienne Chatenoud
• 43 min
  29. The challenge of targeting toxins to tumors

  • Prof. Ben Seon
• 38 min
  30. Antibody depletion therapy in transplantation: implications for tolerance

  • Prof. Laurence Turka
• 36 min
  31. Antibodies as anti-virals

  • Prof. Dennis Burton

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Potential advantages of mAb
3. Challenges for mAb
4. Antibody based therapeutic proteins
5. Immunoligand
6. Attributes of immunoligands
7. Immunoligands can be readily designed
8. Creation of Ig-based fusion proteins
9. Creation of cytolytic human IL-2/Fc fusion protein
10. Creation of non-cytolytic IL-2/Fc fusion protein
11. CTLL-2 proliferation assay
12. Altering biological functions of Fc region (1)
13. Altering biological functions of Fc region (2)
14. IL-2/Fc circulating half-life
15. Non-cytolytic IL-2/Fc fusion protein
16. Vaccine trial design
17. Vaccine trial results
18. Cytolytic IL-2/Fc blocks autoimmunity
19. Creating cytolytic IL-15R antagonist fusion protein
20. IL receptors subunits
21. Role of glutamines found in T cells growth factors
22. Creating cytolytic IL-15 mutant/Fc fusion protein
23. Mutant IL-15/Fc inhibits IL-15 mediated cell growth
24. Creating transplant tolerance
25. Application of immunoligand
26. Challenges for immunoligands

Topics Covered

• Potential advantages of mAB
• Challenges for mAB
• Antibody based therapeutic proteins
• Attributes of immunoligands
• Creation of Ig-based fusion proteins
• Non-cytolytic IL-2/Fc fusion protein
• Vaccine trial design
• Creation of cytolytic IL-15R antagonist fusion protein
• Application of immunoligand: immunogen for mAB production, to stain the cognate ligand, to identify cell surface cognate ligands via immunoprecipitation, to create long lived proteins to test the function of the targeting ligand in vivo and to modulate immune responses
• Challenges for immunoligands

Links

Series:

• Monoclonal Antibodies as Therapeutic Agents

Categories:

• Clinical Practice
• Immunology

Therapeutic Areas:

• Immunology & Inflammation

Talk Citation

Publication History

• Published on October 1, 2007
• Archived on June 13, 2019

Financial Disclosures

• Prof. Terry Strom has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.